The knives were out for Zealand Pharma this week. The Danish biotech, once a darling of the obesity drug race, saw its stock crater 22% on Wednesday, then another 18% on Thursday. Two worst days on record. The trigger? A mid-stage trial readout for its experimental GLP-1/GIP dual agonist that left analysts cold.
The drug, ZP-659, showed respectable weight loss — around 14% after 24 weeks — but the market wanted more. Novo Nordisk's Wegovy delivers north of 15% and Ozempic's oral version isn't far behind. Eli Lilly's Mounjaro hits 20%+. In this game, second best is a participation trophy, and investors don't do participation.
The Data That Broke the Back
Zealand's trial enrolled 280 obese patients. The primary endpoint was met: statistically significant weight loss versus placebo. But the magnitude disappointed. Worse, the dropout rate hit 18% thanks to gastrointestinal side effects — nausea, vomiting, diarrhea. That's a red flag in a market where tolerability is king.
"If you're not beating Novo and Lilly on efficacy, you better have a cleaner safety profile," said Dr. Michael Chen, a biotech analyst at SVB Securities. "Zealand had neither."
The stock never recovered. By Friday it was trading at 385 Danish kroner, down from a peak of 720 kroner in March. The company's market cap evaporated by nearly $4 billion in 48 hours.
"If you're not beating Novo and Lilly on efficacy, you better have a cleaner safety profile. Zealand had neither."
Enter Amylin: The Hail Mary
But Zealand isn't a one-trick pony. Buried in its pipeline is a drug called ZP-812, an amylin analog. Amylin is a hormone that complements GLP-1 by slowing gastric emptying and promoting satiety. It's not new — Amylin Pharmaceuticals had a drug called Symlin back in the 2000s — but it never took off because it required multiple daily injections.
Zealand's version is long-acting. Once-weekly. And early data suggests it could be a game-changer. In a Phase 1b trial, ZP-812 combined with semaglutide (the active ingredient in Ozempic) produced weight loss of 17% over 12 weeks — better than either drug alone. Investors are now treating this as Zealand's last, best hope.
"The amylin data is legit," said Priya Singh, portfolio manager at HealthCap. "If they can replicate that in Phase 2, the stock doubles from here. If they fail, they're an acquisition target at best."
The next readout is expected in Q4 2026. Between now and then, Zealand's stock will be a yo-yo, swinging on every rumor and analyst note. But the amylin story gives it a floor — for now.
The Bigger Picture: A Market That Eats Its Own
The obesity drug market is projected to hit $100 billion by 2030. But it's already consolidating. Novo Nordisk and Eli Lilly control 90% of the GLP-1 market. Pfizer, Roche, and Amgen are scrambling to catch up. Small biotechs like Zealand are caught in the crossfire.
"The market has zero patience for incremental innovation," said James Harlow, a healthcare analyst at Bernstein. "The bar is set by the leaders. If you're not clearly better, you're irrelevant."
That's harsh, but true. Zealand's GLP-1/GIP drug was never going to topple Wegovy. It might have carved out a niche in patients who don't respond to existing therapies, but the sell-off shows that niche isn't big enough to sustain a $15 billion valuation.
Meanwhile, the amylin story is gaining traction across the industry. Novo Nordisk has its own amylin candidate in early trials. Eli Lilly is exploring combinations. But Zealand is the pure play — if ZP-812 works, it could be a $20 billion drug. If it doesn't, the company is worth maybe $2 billion as a pipeline filler for a bigger player.
What's Next: Buy the Dip or Run for the Hills?
After the crash, Zealand trades at a forward price-to-sales ratio of 8x — cheap by biotech standards, but only if you believe in the amylin thesis. Without it, the company has no near-term catalysts and a cash burn that will require another capital raise within 12 months.
Insiders have been buying. CEO Adam Steensberg purchased 50,000 shares on Thursday, spending $2.5 million of his own money. That's a bullish signal, but insiders have been wrong before.
Short interest stands at 12% of float, up from 4% a month ago. The shorts are circling, betting the amylin data will disappoint. If they're right, the stock could fall another 30%. If they're wrong, a short squeeze could send it back to 600 kroner overnight.
So what should you do? If you're a speculator, this is a binary bet on a single data readout. Position size accordingly. If you're an investor, wait for the amylin data. Don't catch a falling knife just because it's cheap.
Zealand Pharma is now a penny stock in all but name — a high-stakes gamble on a hormone that could make it or break it. That's not investing. That's gambling. And in this market, the house usually wins.
